The majority of patients with neuroblastoma have tumors that initially respond to chemotherapy, but a large proportion will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole-genome sequencing of 23 paired diagnostic and relapse neuroblastomas showed clonal evolution from the diagnostic tumor, with a median of 29 somatic mutations unique to the relapse sample. Eighteen of the 23 relapse tumors (78%) showed mutations predicted to activate the RAS-MAPK pathway. Seven of these events were detected only in the relapse tumor, whereas the others showed clonal enrichment. In neuroblastoma cell lines, we also detected a high frequency of activating mutations in the RAS-MAPK pathway (11/18; 61%), and these lesions predicted sensitivity to MEK inhibition in vitro and in vivo. Our findings provide a rationale for genetic characterization of relapse neuroblastomas and show that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease.
A r t i c l e s
Neuroblastoma is a pediatric tumor of the peripheral sympathetic nervous system. Tumor behavior varies from spontaneous regression to incurable progression. Patients with high-risk neuroblastoma have a survival rate of less than 50% (refs. 1,2), despite extensive treatment involving chemotherapy, surgery, radiation therapy and immunotherapy. In a majority of patients, an initial response to therapy is observed; however, up to 60% of these patients subsequently relapse with therapy-resistant tumors [3] [4] [5] . Genetic alterations including MYCN amplification and segmental chromosome alterations such as 1p deletion, 11q deletion or 17q gain are associated with poor prognosis [6] [7] [8] [9] ; however, it is unknown which genetic defects are associated with disease relapse.
Thus far, DNA obtained from 389 primary neuroblastomas at the time of diagnosis has been profiled by next-generation Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations sequencing techniques [10] [11] [12] [13] . These studies documented a relative paucity of somatic mutations, with activating mutations in ALK and inactivating mutations in ATRX being most frequent but with mutations in each of these genes occurring in less than 10% of the cases studied. These studies challenge the notion of precision medicine based on somatic genetic alterations in primary neuroblastoma tumors alone. Notably, none of these large-scale studies considered the tumor genome at relapse, partly because patients are rarely subjected to a tumor biopsy at the time of disease progression, as current diagnostic radiology techniques such as metaiodobenzylguanidine scintigraphy are highly sensitive and specific 14 .
Recently, sequencing of the ALK locus in neuroblastomas at the time of relapse identified 14 activating mutations in 54 cases (26%) 15 , suggesting that the frequency of ALK aberrations is higher in relapsed neuroblastoma genomes. This implies selection of tumor cells with alterations in genes that mediate neuroblastoma relapse. Therefore, to identify genetic alterations associated with relapsed neuroblastoma, we performed whole-genome sequencing of 23 triplet samples of primary tumor, relapsed tumor and constitutional DNA.
RESULTS

Clonal evolution
We sequenced the genomes of 23 triplet samples constituting primary and relapse neuroblastomas and lymphocytes (Supplementary Table 1 ). Tumors were of all stages and had variable outcome, with the only eligibility criterion being the availability of high-quality DNA from the triplet samples. There was a roughly equal distribution of cases among low-, intermediate-and high-risk groups 5 . The median time from diagnosis to relapse was 11.3 months (range of 1-90 months). Twenty-one of the 23 subjects in this study received chemotherapy before relapse, and 8 also received radiation therapy, according to internationally accepted treatment protocols (Table 1) . Thus, all patients underwent similar chemotherapy regimens, with high-risk patients additionally receiving radiation therapy and highdose chemotherapy with stem cell rescue. No patient on this study received targeted inhibitors to any oncogenic pathway between the time of diagnosis and relapse. The majority of low-risk cases received chemotherapy because of the site and/or size of the primary tumor.
We analyzed the sequence data for somatic mutations resulting in amino acid changes or located in splice-site regions within 3 bp of an exon, as well as for focal structural aberrations of regions containing five genes or fewer (Supplementary Tables 2-4 ). There was a median of 14 more mutations in the relapsed samples than in the samples at diagnosis ( Fig. 1 and Supplementary Fig. 1 ). On average, 28% of the mutations detected in the primary tumor were also detected at relapse, showing that the primary and relapsed tumors were of common descent. To gain more insight into the clonal architecture, we estimated the cancer cell fraction (CCF) of all somatic mutations using a customized reimplementation of a previously described Bayesian approach 16 , which infers CCF from mutant allele fractions determined by sequencing and accounts for contamination and locus-specific copy number. This analysis yielded a median CCF of 61% for mutations detected in the primary tumor but lost in the relapse tumor, in comparison to a median CCF of 90% for primary tumor mutations shared with the relapse tumor (Supplementary Fig. 2a) , a pattern that is consistent with subclonal outgrowth of the relapsed tumor. Furthermore, we estimated a median CCF of 83% for all relapse tumor mutations in comparison to a median CCF of 75% for all primary tumor mutations, indicating clonal enrichment of a subset of mutations at relapse (Supplementary Fig. 2b) . Comparison of genes affected by smaller structural events and chromosomal copy number alterations in primary and paired relapse tumors showed similar results, with a subset of aberrations shared but many detected only in the primary or relapse tumor (Fig. 1c,d, Supplementary Fig. 3 and Supplementary Table 4 ).
Enrichment of mutations that activate RAS-MAPK signaling
Unbiased pathway analysis 17 using whole-genome sequencing data from the relapse samples on a per-patient basis identified a strong enrichment (P = 6.1 × 10 −7 ) for mutations in genes associated with RAS-mitogen-activated protein kinase (MAPK) signaling (Supplementary Table 5 ). We next filtered the identified mutated genes against the Cancer Gene Census 18 and subsequently focused on hotspot regions by selecting mutations annotated in the Catalogue of Somatic Mutations in Cancer (COSMIC) to identify events that are well annotated to activate this pathway. Fifteen of 23 relapse samples contained somatic mutations that met these criteria. In addition, three relapse samples showed structural alterations involving these RAS-MAPK pathway genes; thus, we detected aberrations in this pathway in 18 of 23 relapse samples (78%), and all alterations were consistent with pathway activation ( Table 2) . Eleven mutations activating RAS-MAPK signaling that were present in primary tumors were all preserved in the corresponding relapse tumors. Seven mutations were not detectable in the primary tumor at the sequencing depth achieved, and we therefore employed ultra-deep sequencing to determine whether these mutations were present in fractions under the whole-genome sequencing detection limit. The ALK mutation in N607 was found in the primary tumor, whereas the other mutations were undetectable (Supplementary Fig. 4a ). We assayed structural aberrations using PCR-based methods. Only the ALK rearrangement in N790 was shown to be present at low frequency in the primary tumor (Supplementary Fig. 4b) .
ALK aberrations occurred in ten relapse tumors and were also detected by whole-genome sequencing in seven of the corresponding primary tumors. All detected single-nucleotide variants (SNVs) have been proven to constitutively activate this receptor tyrosine kinase known to activate RAS-MAPK signaling 19 . Furthermore, one relapse sample showed a de novo amplification giving rise to a PPM1G-ALK fusion gene, which activated the RAS-MAPK pathway when expressed in neuroblastoma cell lines (Supplementary Fig. 5) .
Two tumors showed relapse-specific inactivation of the NF1 tumor-suppressor gene, through homozygous deletion in one case and heterozygous deletion combined with a splice-site mutation in the other (Supplementary Fig. 6 ). NF1 inactivation has been reported in neuroblastoma and confers activation of RAS-MAPK signaling and resistance to retinoic acid 20 . One pair of primary and relapse tumors showed a heterozygous mutation in PTPN11. Mutations in PTPN11 activate RAS-MAPK signaling, and the identified mutation encoding a p.Ala72Thr substitution has been reported in leukemia and neuroblastoma 12, 21 .
One relapse tumor showed a tandem duplication in the BRAF gene that was not detected in the primary tumor. This rearrangement leads to expression of a BRAF transcript that encodes an elongated protein with two kinase domains. Expression of this BRAF gene with a tandem duplication in a neuroblastoma cell line induced activation of the RAS-MAPK pathway (Supplementary Fig. 7 ). Taken together, the somatic mutations detected in this case series shown to activate the RAS-MAPK pathway were mutually exclusive, with no case having two somatic events known to hyperactivate this growth-promoting pathway.
We hypothesized that mutations activating RAS-MAPK signaling exhibit relapse-specific enrichment due to treatment. We therefore A r t i c l e s npg A r t i c l e s performed a clonality analysis, comparing CCF estimates for RAS-MAPK mutations in paired primary (CCF p ) and relapse (CCF r ) tumors ( Fig. 2 and Supplementary Fig. 8 ). RAS-MAPK mutations were almost universally present within major subclonal populations at relapse, as indicated by CCF r > 0.5 with probability >90% under the posterior distribution for 14 of 15 relapse tumors. In 7 of 15 tumor pairs, there was strong evidence of relapse-specific enrichment of RAS-MAPK mutations-including mutations in ALK (4 pairs), HRAS (1 pair), KRAS (1 pair) and NF1 (1 pair)-based on a criterion of CCF r > CCF p with probability >90% for each pair. By contrast, the probability that CCF r > CCF p fell within 20-80% bounds for the remaining eight pairs, indicating that RAS-MAPK mutations that were already present in the primary tumor were retained at relapse. Collectively, these results support RAS-MAPK mutations as somatic drivers that undergo positive selection over the course of neuroblastoma treatment.
Chromosomal aberrations
Three relapse samples showed homozygous deletions in the CDKN2A locus, encoding the tumor-suppressor proteins p14 ARF and p16, whereas both alleles of CDKN2A were present in the corresponding primary tumors (Supplementary Fig. 9 ). CDKN2A deletions were previously reported as frequent events in neuroblastoma relapse 22 . We detected other relapse-specific segmental chromosome defects, including loss of 6q (five cases) and loss of 17p (three cases). Furthermore, we detected relapsespecific aberrations that are frequently detected in primary neuroblastoma and are associated with poor prognosis, including loss of chromosomes 1p (one case) and 11q (three cases) (Fig. 1c and Supplementary Fig. 3 ) 7, 9 .
RAS-MAPK pathway mutations and sensitivity to MEK inhibition
To determine whether neuroblastoma cell lines contain RAS-MAPK mutations, we analyzed whole-genome sequencing data from a series of human-derived neuroblastoma cell lines for mutations in ALK, NRAS, HRAS, KRAS, BRAF, PTPN11 and NF1. Eleven of the 18 cell lines showed such mutations ( Supplementary Fig. 10 and Supplementary Table 6) .
We tested our cell line panel for sensitivity to the MEK inhibitors trametinib, cobimetinib and binimetinib, to determine the relationship between mutation status and drug sensitivity. The data showed clustering of the cell lines into four groups with increasing sensitivity to MEK inhibition: (i) lines without RAS-MAPK mutations; (ii) lines with ALK mutations; (iii) lines with NF1 mutations; and (iv) lines with RAS gene or BRAF mutations (Supplementary Fig. 11 ). In the cell lines with mutated RAS genes or BRAF, MEK inhibitor treatment caused almost complete cell cycle arrest at low nanomolar concentrations, whereas in the NF1-and ALK-mutated lines the effect on cell cycle inhibition was less robust (data not shown). When the sensitivity of the cell lines was expressed as the concentration at which cell growth was inhibited by 50% (GI 50 ), there were significant differences between cell lines with and without RAS-MAPK mutations ( Fig. 3a-c) .
GI 50 values for the three different compounds were highly correlated in the cell line panel (Supplementary Fig. 12 ), suggesting an on-target effect (r 2 = 0.49-0.79; P < 0.01). A relationship between mutation status and sensitivity to MEK inhibition was also observed in an independent published data set 23 (Supplementary Fig. 13 ).
To validate that ALK and RAS gene mutations directly activate the RAS-MAPK pathway in neuroblastoma cells, we induced 
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A r t i c l e s Fig. 14) . We have shown previously that knockdown of NF1 causes hyperactivated RAS-MAPK signaling in neuroblastoma cell lines 20 .
We next treated various human neuroblastoma-derived cell line xenograft models, representing the four groups described above, with the MEK inhibitor binimetinib. SK-N-AS xenografts, which harbor an NRAS mutation encoding p.Gln61Lys, showed inhibition of tumor growth and increased survival when treated with binimetinib, in a dose-dependent fashion (Fig. 3d) . NBL-S xenografts have an inactivating mutation in one allele of NF1 and an almost complete absence of NF1 protein expression ( Supplementary Fig. 15) ; these xenografts also showed inhibition of growth with treatment. Conversely, treatment of Kelly and IMR-5 xenografts had no effect on tumor growth. IMR-5 cells do not have RAS-MAPK pathway mutations detectable by whole-exome sequencing (data not shown), whereas Kelly cells harbor an ALK mutation encoding a p.Phe1174Leu substitution.
We then determined whether inhibition of cell growth corresponds with inhibition of the RAS-MAPK pathway in the cell lines that were used for the mouse xenograft experiments. We treated the cell lines with increasing concentrations of binimetinib in vitro for 24 h and screened for ERK phosphorylation (Supplementary Fig. 16 ). The three lines with RAS-MAPK mutations showed phosphorylation of ERK under untreated conditions, reaffirming that these mutations indeed lead to activation of the RAS-MAPK pathway. Upon exposure to binimetinib, SK-N-AS and NBL-S cells showed a dosedependent decrease in the levels of phosphorylated ERK, whereas Kelly cells showed no significant change. These data suggest that the minimal effect of MEK inhibition in vitro and the absence of an effect in vivo for the Kelly cell line may be due, at least in part, to continued 
Primary Relapse Figure 2 RAS-MAPK pathway mutations reside within major relapsed neuroblastoma subclones. Each of the 15 panels represents a primary-relapse pair with a corresponding RAS-MAPK pathway mutation. Posterior distributions of CCF were computed by the method of Carter and colleagues 16 and are represented by violin plots, with black dots positioned at the distribution medians. Four primary-relapse pairs (NB1382, PASGAP, N607 and PARBAJ) possess relapse-specific RAS-MAPK pathway mutations that are undetectable in the corresponding primary tumors by whole-genome sequencing. Three additional pairs (NB1224, NB308 and PAPVEB) also show evidence of relapse-specific enrichment of RAS-MAPK mutations based on the criterion that the probability of CCFr > CCFp was >90% for each pair. CCF estimates for ALK mutations in NB308 reflect p.Phe1174Leu (c.352C>A) and p.Phe1174Leu (c.352C>G) substitutions in the primary and relapse samples, respectively, as previously described 15 .
A r t i c l e s ERK phosphorylation. To confirm that the response we observed in vivo was also due to target inhibition, we analyzed ERK phosphorylation in the xenografts that responded to treatment and demonstrated a dosedependent decrease in the levels of phosphorylated ERK (Supplementary Fig. 17 ).
DISCUSSION
Recent studies using next-generation sequencing methodologies indicate, first, a low mutation rate in primary neuroblastoma tumors, with a mean of 15 nonsynonymous mutations per sample, and, second, a paucity of recurrently affected genes [10] [11] [12] [13] . Because relapsed highrisk neuroblastoma tumors often demonstrate substantial resistance to chemotherapy and are typically lethal, we hypothesized that the mutational spectrum of relapsed disease would be different than that for primary tumors and might mediate therapy resistance. In this study, we characterized the genomes of 23 relapsed neuroblastomas and compared each to the genome of the corresponding primary tumor. We show that the relapsed tumors generally contain more mutations and structural aberrations and that clonal selection takes place between the primary tumor and the relapse tumor. We found that 18 of 23 relapse tumors harbored mutations predicted to hyperactivate the RAS-MAPK signaling pathway and that cell lines containing similar mutations show sensitivity to inhibition of MEK, a downstream node in the canonical growth-promoting pathway. These results provide a strong rationale for recommending biopsy and genomic characterization of relapsed neuroblastoma tumors and for prioritizing the clinical testing of MEK inhibition strategies in the treatment of relapsed neuroblastoma.
Because of the sensitivity and specificity of modern imaging modalities, the diagnosis of neuroblastoma relapse rarely requires a tumor biopsy. In addition, until recently, there has been no realistic potential for therapeutic benefit based on biopsy results, and therefore very few relapse neuroblastoma samples are available for study. Here we collected high-quality material from 23 primary-relapse tumor pairs across the spectrum of neuroblastoma phenotypes, including those assigned to high-, intermediate-and low-risk groups 5 . The only inclusion criterion for this study was the availability of matched samples, but some cases may have been biopsied owing to an unusual clinical course. Indeed, there were a fairly high number of intermediate-and low-risk tumors that normally do not show frequent relapse 5 . However, the frequency of RAS-MAPK mutations did not differ among the groups, so it is unlikely that the overrepresentation analysis is influenced by this bias.
The high frequency of RAS-MAPK pathway mutations at diagnosis in this cohort was unexpected, as such high frequencies were not reported in whole-genome sequencing series of primary tumors [10] [11] [12] [13] . It is possible that the presence of these lesions in a diagnostic sample is a biomarker of a more aggressive clinical course and a higher likelihood of relapse. These findings need to be validated in a prospective patient cohort.
We detected several recurrent structural aberrations at the time of relapse. Partial loss of chromosome 6q was observed in five relapse samples, and homozygous deletion of CDKN2A was found in three relapse samples. Both events are infrequent in primary neuroblastoma and present interesting targets for further research. Furthermore, neuroblastoma-associated aberrations such as loss of 1p and 11q were observed in the relapse tumor and not in the primary tumor, indicating that these events might not be tumor initiating but rather are crucial steps in neuroblastoma tumor evolution 24 .
Events affecting RAS-MAPK signaling were detected in 18 of 23 relapse samples. In four cases, we identified structural variants, highlighting the benefit of whole-genome sequencing for detection of the full spectrum of genetic alterations. In 7 of these 18 cases, the mutations were observed only in the relapse tumor, which indicates that analysis of primary tumor samples is not sufficient to guide the choice of treatment for neuroblastoma relapses. These findings are in line with the de novo occurrence of ALK mutations reported previously 15 .
The observation that several RAS-MAPK mutations were present in the relapse tumor but not in the corresponding primary tumor favors a model where subclones with secondary driver mutations expand over time, possibly under the selective pressure of chemotherapy, as was recently described for chronic lymphocytic leukemia 25 . Whether these mutations occurred between diagnosis and relapse, were present at levels below detection limits or were undetectable owing to spatial heterogeneity in the primary tumor remains to be determined. table 6 ). Red bars represent the mean GI 50 value for each group.P values were derived from Kruskal-Wallis tests. Student's t tests were performed to determine differences between non-mutated and mutated groups: *P < 0.05, **P < 0.01, ***P < 0.001. (d) Human neuroblastoma-derived SK-N-AS, NBL-S, Kelly and IMR-5 xenografts were treated with binimetinib (3 mg/kg or 30 mg/kg) or vehicle by oral gavage twice daily. Each cohort consisted of ten mice, and tumor volumes (cm 3 ) and percent survival are shown. Error bars, s.e.m.; significance is denoted: *P < 0.05.
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A r t i c l e s
It has been firmly established that mutations in the RAS-MAPK pathway can occur as resistance mechanisms against treatment with targeted kinase inhibitors 26 ; however, no targeted inhibitors were used in the treatment of our patient cohort. Mutations in the RAS-MAPK pathway may also be associated with resistance to conventional cytotoxic therapies in neuroblastoma, but more research is needed to establish the molecular basis of this phenotype.
The ALK gene was mutated in ten relapse samples, and it is known that the most frequent ALK mutations in neuroblastoma activate the RAS-MAPK signaling pathway 27 . The results of our xenograft therapeutic studies indicate that single-agent treatment with a MEK inhibitor might not be effective in ALK-mutated tumors. However, the finding that ALK-mutated cell lines consistently showed some sensitivity to MEK inhibition in vitro suggests that activated RAS-MAPK signaling does have a role in ALK-mutated neuroblastoma and warrants further investigation on the use of MEK inhibitors in combination therapies. ALK inhibitors have proven to be effective in the treatment of ALKmutated tumors 28 , but some mutations are associated with resistance to currently available ALK inhibitors 19 . Therefore, combined MEK and ALK inhibition might improve response in tumors containing such mutations. Combination of these inhibitors with ones targeted against other pathways that are activated in ALK-mutated neuroblastoma, such as phosphoinositide 3-kinase (PI3K) and mTOR 29, 30 signaling, might also improve therapeutic efficacy.
We also detect mutations in NF1, BRAF, PTPN11, FGFR1 and the three RAS genes, and all lesions in the RAS-MAPK pathway were mutually exclusive. Cell lines with RAS-MAPK mutations show moderate to high sensitivity to MEK inhibitors, and treatment with the inhibitor binimetinib of SK-N-AS xenografts, which contain an NRAS mutation, as well as NBL-S cells, which have loss of NF1, results in significant therapeutic efficacy. These findings suggest that MEK inhibition might be of clinical benefit in the treatment of neuroblastoma relapses containing RAS-MAPK mutations.
Our study provides a strong rationale for performing biopsies and genomic characterization of relapsed neuroblastomas, with the prospect of direct patient benefit. We show that RAS-MAPK pathway mutations occur frequently in relapsed neuroblastoma and propose matching such pathway lesions to novel therapies such as MEK inhibition. A prospective clinical trial in which biopsy and nextgeneration sequencing are used for the selection of a targeted therapy will be required to determine the clinical implication of this newly defined genetic landscape of relapsed neuroblastoma.
URLs. R2 bioinformatics platform, http://r2.amc.nl/; Exome Variant Server (EVS), http://evs.gs.washington.edu/EVS/.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The whole-genome sequencing data have been deposited at the European Genome-phenome Archive (EGA) under accession EGAS00001001184 for the French cases and under accession EGAS00001001183 for the Dutch cases. Sequence data for the US cases are available in the database of Genotypes and Phenotypes (dbGaP) under accession phs000467. Whole-exome sequencing data for neuroblastoma cell lines are available through the Sequence Read Archive (SRA) under BioProject PRJNA282395. 
ONLINE METhODS
Sample collection and patient selection. The inclusion criteria for this study were histopathological confirmation of neuroblastoma at original diagnosis and the presence of biopsy material from a subsequent relapse specimen. Patients were included in this study after obtaining informed consent from parents or guardians, with oversight from the ethics committees 'Comité de Protection des Personnes Sud-Est IV' , reference L07-95/L12-171, and 'Comité de Protection des Personnes Ile-de-France' , reference 0811728 in France, the review board at the Children's Hospital of Philadelphia and review boards at other Children's Oncology Group sites that submitted samples for patients on this study in the United States, and the review board of the Academic Medical Center of the University of Amsterdam in the Netherlands. Somatic ALK mutation status has been reported for samples FR_NB0175 ,  FR_NB308, FR_NB399, FR_NB1224, FR_NB1269 and FR_NB13821 (ref. 15) .
Whole-genome sequencing, summary. Whole-genome sequencing was performed by Complete Genomics to an average coverage of 50× per sample (for Dutch and US patient material and cell line material) 31 or using Illumina HiSeq 2500 instruments to an average coverage of 80× per sample (for French patient material). Material for each patient (lymphocytes, primary tumor and relapse tumor) was in all cases sequenced using the same sequencing platform. Details on sequencing results are given in Supplementary Table 1 . Estimation of normal tissue contamination and whole-genome segmentation was performed on all primary-normal and relapse-normal pairs with Sequenza software v2.1.0 using both binned coverage ratio data and SNV allelic ratios as input 32 . Coverage-based copy number plots were generated as previously described 11 , with the exception that values were corrected for ploidy and purity as determined by Sequenza. The R2 bioinformatics platform and Circos 33 were used for analysis and visualization. Subclonal detection of variants is described in the Supplementary Note. Whole-genome sequencing, Complete Genomics. Potential somatic variants were determined with the CallDiff algorithm with somatic output as available in the CGAtools v1.3.0 package, maintained by Complete Genomics. Every tumor was compared to its matched blood sample across the genome. The somatic output files were then filtered to regions where coding sequences are defined in the UCSC refflat. Silent mutations were subsequently removed from the analysis. In addition, we determined the presence of somatic splicesite variants in the three bases surrounding exons as defined by UCSC refflat data. Variants with a somatic score >0.05 (for NL_041, NL_571 and NL_N607) or Somatic Quality high (the remainder of the patients) were included in the analysis.
Comparisons of structural variants between tumor and lymphocyte genomes were performed with the JunctionDiff and Junction2Event algorithms from CGAtools. These somatic events were filtered to remove events matching the following criteria: events annotated as artifacts, footprints smaller than 70 bases, less than 10 discordant mate pairs, under-represented repeats and presence in a set of baseline genomes (as provided on the website of Complete Genomics (B36baseline-junctions.tsv)). Of the remaining entries, we kept the following events: (i) exon_bites, where both ends of a junction were within the same gene and in addition affect an exonic sequence, (ii) breaks by inversion, where both ends of a junction land within a gene, thereby damaging both genes but leaving the genes in between unaffected, (iii) potential fusion genes, which are strand matched, where both ends of a junction landed within a gene and the resulting end product fit in terms of orientation of both genes, and (iv) regions (deletions or (tandem) duplications) of up to 1 Mb, containing up to five genes.
Whole-genome sequencing, Illumina. Whole-genome sequencing was performed using an Illumina HiSeq 2500, with 90-bp paired-end reads for six tumors and 100-bp paired-end reads for the remaining two tumors. After alignment with hg19 using Burrows-Wheeler Aligner (BWA) 34 , bam files were cleaned according to Genome Analysis Toolkit (GATK) recommendations 35 .
Variant calling was performed in parallel using three variant callers: GATK 2.2-16, SAMtools 0.1.18 and MuTect 1.1.430 (refs. 34-36) . ANNOVAR v2012-10-23 (ref. 37 ) with COSMIC v64 and dbSNP v137 was used for annotation. SNVs with a quality under 30, a depth of coverage under 6 or with fewer than 2 reads supporting the variant were filtered out, as were variants reported in more than 1% of the population in the 1000 Genomes Project 38 or Exome Sequencing Project (Exome Variant Server, National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project (ESP)).
Variants were then filtered to those regions where coding sequences are defined or to variants in the three bases surrounding exons. Silent mutations were subsequently removed from the analysis. Tumor and corresponding constitutional genomes were compared using the SAMtools mpileup algorithm 34 , and non-somatic variants were discarded from the analysis.
Structural variants, including deletions, inversions, tandem duplications and translocations, were analyzed using DELLY v0.5.5 with standard parameters 39 . In tumors, at least ten supporting reads were required to make a call, and five supporting reads were required for sample NB0175 with a coverage of only 40×. To predict structural variants in constitutional samples for subsequent somatic filtering, only two supporting reads were required. To identify somatic events, all the structural variants in each normal sample were first flanked by 500 bp in both directions and any structural variant called in a tumor sample that was in the combined flanking regions of the respective normal sample was removed. Deletions with more than five genes affected or larger than 1 Mb in size and inversions or tandem duplications covering more than four genes were removed. We focused on exonic and splicing events for deletions, inversions and tandem duplications. For translocations, we kept all structural variants that occurred in intronic, exonic, 5′ UTR, upstream or splicing regions.
Clonality analysis. Estimation of the CCF of somatic mutations was performed using the Bayesian method of Carter et al. to infer posterior intervals without clustering for comparison 25, 40 . Namely, we assumed that the expected allele fraction of a mutation in a sample of tumor purity α, total somatic copy number q and mutation multiplicity s could be expressed as a function of the CCF c, where f(c) = αcs/(2(1 -α) + αq). Given a uniform prior on c, the posterior density of c is therefore proportional to Binom (a|N, f(c) ), where a is the variant read count and N is the total read count. While α and q are estimated by Sequenza, the mutation multiplicity s is generally not known. However, under the parsimonious assumption that a mutation occurs only once within a tumor's evolutionary history, we can bound s by 1 ≤ s ≤ m ≤ q, where m is the major allelic copy number of the mutation locus, which is estimated by Sequenza. We therefore modeled the posterior distribution under two assumptions: s = 1 (biased toward higher clonality estimates) and s = m (biased toward lower clonality estimates).
Estimation of CCF was also performed using PyClone v0.12.7 as an alternative method for comparison 41 . For each primary or relapse tumor, PyClone was run on all somatic coding point mutations using the parental_copy_number method and pyclone_beta_binomial density, with estimates of tumor purity and allelic copy number from Sequenza provided as necessary inputs. The Markov chain Monte Carlo (MCMC) step of PyClone was run for 10,000 iterations with burn-in and thin parameters set to 1,000 and 10, respectively, resulting in 900 independent samples from the posterior distribution of CCF per mutation. Otherwise, default options for PyClone were used.
Cancer mutation analysis. To identify pathways or processes that were frequently affected in neuroblastoma relapse tumors, we used the CancerMutationAnalysis R package 17 . Somatic mutations detected only in the relapse sample and detected in the relapse and primary samples for all tumors were used as input. This algorithm is not suitable for the analysis of structural variants, so these were not included. P values were generated using the permutation null method without heterogeneity and signify the enrichment of mutated genes associated with a certain Gene Ontology (GO) Biological Process category across all relapse tumors.
Cell lines. All cell lines were cultured in DMEM or RPMI-1640 supplemented with 10% FBS, 20 mM l-glutamine, 10 U/ml penicillin and 10 µg/ml streptomycin and maintained at 37 °C under 5% CO 2 . Cell line identities are regularly confirmed by short tandem repeat (STR) profiling using the PowerPlex16 system and GeneMapper software (Promega). Cell lines are regularly screened for the presence of mycoplasma. Inducible expression of RAS-MAPK mutants is described in the Supplementary Note. npg e r r ata Erratum: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
